Franchise opportunities compared
Amerisourcebergen Drug vs PayMore
Reviewed figures from each brand's Franchise Disclosure Document (FDD), side by side. Each figure carries its FDD year and page. This is not a ranking or recommendation, and the two FDDs may cover different years and location groups.
Initial investment · Item 7
Amerisourcebergen Drug
$5,000 – $12,000
2026 FDD · Item 7 · PDF p. 29PayMore
Not available
Initial franchise fee · Item 5
Amerisourcebergen Drug
Not available
PayMore
Not available
Royalty · Item 6
Amerisourcebergen Drug
Not available
PayMore
$1,000
2026 FDD · Item 6 · PDF p. 10Before you compare
- Both sets of figures come from 2026 FDDs.
- Only PayMore has reviewed Item 19 figures here.
Financial commitment
Amerisourcebergen DrugAmerisourcebergen Drug
PayMore
Amerisourcebergen Drug
PayMore
Amerisourcebergen Drug
PayMore
Amerisourcebergen Drug
PayMore
System scale & health
Amerisourcebergen DrugAmerisourcebergen Drug
PayMore
Amerisourcebergen Drug
PayMore
Amerisourcebergen Drug
PayMore
Amerisourcebergen Drug
PayMore
Amerisourcebergen Drug
PayMore
Financial performance (Item 19), by location group
Amerisourcebergen DrugNo reviewed Item 19 figures
Item 19 groups are shown separately and never combined. Revenue or sales figures are not profit. Net outlet change and turnover are Franopolis calculations from the disclosed counts; turnover is a count-based rate, not a measure of owner earnings.
Amerisourcebergen Drug vs PayMore: common questions
- Which has more locations, Amerisourcebergen Drug or PayMore?
- Amerisourcebergen Drug: 2,361 (2026 FDD · Item 20 · PDF p. 55); PayMore: 1 (2025 FDD · Item 20 · PDF p. 50). Total outlets from Item 20. Outlet counts do not indicate territory availability or franchisee results.
- Do Amerisourcebergen Drug and PayMore disclose financial performance (Item 19)?
- Amerisourcebergen Drug has no reviewed Item 19 figures on file; PayMore has reviewed Item 19 figures for 55 location groups. Different location groups are not directly comparable, and revenue is not profit.
Answers restate the reviewed figures above. Not a ranking or recommendation.
Keep researching

Full Amerisourcebergen Drug report
Every reviewed fee, Item 19 group, outlet table and territory disclosure
Full PayMore report
Every reviewed fee, Item 19 group, outlet table and territory disclosure

